Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.295 CAD | 0.00% | 0.00% | -68.28% |
04-24 | Antibe Therapeutics Inc. Announces Board Resignations | CI |
04-19 | Antibe Therapeutics Seeks Extension of Stay of Proceedings | MT |
Business Summary
Number of employees: 11
Managers
Managers | Title | Age | Since |
---|---|---|---|
Alain Wilson
DFI | Director of Finance/CFO | - | 30/11/15 |
Chief Tech/Sci/R&D Officer | - | - | |
Ana Stegic
CTO | Chief Tech/Sci/R&D Officer | - | - |
Scott Curtis
COO | Chief Operating Officer | - | 31/12/15 |
Joseph Stauffer
CTO | Chief Tech/Sci/R&D Officer | 58 | 05/05/20 |
Investor Relations Contact | - | - | |
David Vaughan
PRN | Corporate Officer/Principal | 74 | 31/10/12 |
Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 50 | 23/11/20 | |
Amal Khouri
BRD | Director/Board Member | - | 18/03/18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 53,009,362 | 48,801,128 ( 92.06 %) | 0 | 92.06 % |
Company contact information
Antibe Therapeutics, Inc.
15 Prince Arthur Avenue
M5R 1B2, Toronto
+416-922-3460
http://www.antibethera.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-68.28% | 11.42M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- ATE Stock
- Company Antibe Therapeutics Inc.